# Hedera Dx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hedera-dx

- Industry: Healthcare IT
- Headquarters: Epalinges, Switzerland
- Website: www.hederadx.com
- Total disclosed funding: $31M
- Latest round: Series A (May 27, 2025)
- Investors on record: 9

## About

Based in Switzerland, and founded in 2021 by its CEO, Tommi Lehtonen, CCO, Damien Lapray, CMO, and Christian Meisel, Hedera Dx SA, operates as a healthcare technology company that offers liquid biopsies for cancer patients having therapies. In May 2025, Hedera Dx SA raised EUR 15 million in series A funding led by new investor VSquared Ventures, with participation from another new investor Tesi. Returning investors Helsana HealthInvest, Eyrir Invest, Inventure, and Top Harvest Capital also participated in the round. The company offers a liquid biopsy solution that includes blood drawing and sequencing for personalized treatment plans for circulating tumors. The company also provides a platform that helps to generate a patient’s tumor ctDNA sequence. The company will use the May 2025 funding to develop a new liquid biopsy test for cancer.

## Funding rounds

- Series A, May 27, 2025, $17M — Tesi, Inventure, Eyrir Invest, Vsquared Ventures, Top Harvest Capital, Helsana HealthInvest
- Seed, Sep 21, 2022, $14M — Inventure, Air Street Capital, Amino Collective, GRIDS Capital

## Investors

- Inventure (https://capitalatlas.ai/funds/inventure) — Seed, Series A
- Air Street Capital (https://capitalatlas.ai/funds/air-street-capital) — Seed
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Seed
- GRIDS Capital — Seed
- Tesi (https://capitalatlas.ai/funds/tesi) — Series A
- Eyrir Invest (https://capitalatlas.ai/funds/eyrir-invest) — Series A
- Vsquared Ventures (https://capitalatlas.ai/funds/vsquared-ventures) — Series A
- Top Harvest Capital (https://capitalatlas.ai/funds/top-harvest-capital) — Series A
- Helsana HealthInvest — Series A